The Veterinary Development Council (VDC) is conducting a survey to investigate the role of paraprofessionals and technicians in veterinary practice, and is asking vets in large animal, equine, and mixed practices to complete a short survey.
The VDC says that information from the survey will help inform discussions on the regulation of technicians.
The survey will take between 5 and 10 minutes to complete and can be found on the BVA website at www.bva.co.uk/vdc. The BVA has also emailed the survey directly to practices.
The survey has been devised by the VDC working group looking at the role of the veterinary-led team, chaired by BVA Past President Professor Bill Reilly. This is one of three working groups that will report to the VDC:
Professor Reilly said: "The relationship between veterinary surgeons and technicians is vital but it varies from practice to practice.
"The working group on the role of the veterinary-led team aims to take a snapshot of how services, such as artificial insemination and foot trimming, are currently delivered, and gauge how veterinary surgeons feel about other services being delivered by non-veterinarians in the future.
"I hope veterinary surgeons in large, mixed and equine practice will take 10 minutes to complete our survey to help us map the current use of technicians in veterinary practice and help shape our future discussions."
Boehringer Ingelheim VetMedica has published its equine endocrine webinars online for veterinary professionals to view on demand at www.prascend.co.uk/webinars.
The webinars, which cover 'Diagnostic challenges in equine endocrine disease', presented by equine internal medicine specialist Andy Durham from the Liphook Equine Hospital, and 'A problem-based approach to equine laminitis', presented by equine internal medicine specialist Dr Catherine McGowan from the University of Liverpool, are each one hour long.
Participants will each receive CPD certificates for participation.
Dechra Veterinary Products has launched Celox Veterinary, a product which stops arterial or venous haemorrhage within 3 minutes, described as 'revolutionary' by the company.
Celox Veterinary is available in both a granule formulation and in two sizes of gauze. The granules can be poured into a wound. Once pressure is applied, a clot forms and arterial and venous haemorrhage is stopped within three minutes, independent of the body's normal clotting processes. Celox Veterinary Gauze has the granules ready bonded onto its surface for ease of use.
Dechra says the product works by bonding with red blood cells and gelling with fluids to produce a robust clot which sticks to moist tissue to plug the bleeding site. It can be helpful in treating a wide range of veterinary cases including:
Celox Veterinary is made from chitosan, a natural polysaccharide and by-product of the shrimp industry. It generates no heat while in use and small amounts of residual material left in the body are naturally metabolised.
Dechra Product Manager Rachel Horton said: "Wound care is an area in which Dechra is known for its innovative product range. We are delighted to take this to the next level by offering this revolutionary treatment to vets and believe it will soon establish itself as an efficacious tool when they are faced with significant injuries and severe bleeding."
For further information on Celox Veterinary, please contact your Territory Manager or call Dechra direct on (01939) 211200.
Boehringer Ingelheim Vetmedica, manufacturer of the equine pergolide Prascend, has joined forces with the British Horse Society, Redwings Horse Sanctuary and World Horse Welfare to launch the 'Talk About Cushing's (TAC)' campaign.
The initiative, which will take place throughout September and October 2011, is aimed at raising awareness of Cushing's Disease and its clinical signs, perhaps the most familiar of which is hirsutism (abnormal hair growth, or delayed shedding). Horse owners can download a £15 money-off voucher from http://www.talkaboutcushings.co.uk/ throughout the TAC initiative, which can be redeemed through their veterinary practice against blood test costs.
Boehringer says Equine Cushing's Disease, also known as Pituitary Pars Intermedia Dysfunction (PPID), is the most common endocrine disorder in older horses and ponies1 ,and that some estimates suggest over 15% of horses and ponies over 15 years of age are affected2.
Unfortunately, the initial stages of Cushing's Disease are often difficult to detect, delaying the maximum benefit of early diagnosis and intervention. Blood testing is increasingly used to detect the disease and confirm diagnosis, however many horses with clinical signs, including recurrent laminitis, still go undiagnosed.
Craig Beck, vet and equine sales and marketing manager at Boehringer Ingelheim Vetmedica said: "More than 80% of horses suffering from laminitis may have an underlying endocrine disorder, such as Cushing's Disease3.
"The TAC campaign will raise awareness of Cushing's Disease amongst both veterinary professionals and owners. It should make it easier for vets to go ahead with endocrine testing in horses and ponies with recurrent laminitis, diagnosing and treating earlier in the course of the disease."
Lee Hackett, head of welfare at the BHS, added: "Cushing's Disease is relatively common in horses yet in our experience it frequently goes undiagnosed and untreated. This is why we are fully behind the 'Talk About Cushing's' campaign - anything that raises awareness and understanding of this disease has to be of benefit to equine welfare."
Redwings' head of veterinary services Nicky Jarvis said: "At Redwings we have many horses over the age of 15, all living very happy and healthy lives. 'Old age' is not in itself a disease so when a geriatric horse loses condition or appears unwell there is always an underlying cause. If a horse continually succumbs to laminitis or loses weight, Cushing's Disease could be one explanation. However, with early diagnosis, good management and the correct treatment a horse with Cushing's can live comfortably for many years."
"Early diagnosis of Cushing's Disease can be of great benefit, other conditions such as laminitis are often associated with it and it is important that clinical signs are recognised and treated appropriately. World Horse Welfare supports the 'Talk About Cushing's' campaign as it will help people to recognise the signs and take the right action to prevent horses from suffering," concludes Tony Tyler, deputy chief executive, World Horse Welfare.
Backed by an advertising and PR campaign in the equine consumer media, Boehringer Ingelheim Vetmedica has produced a marketing pack for veterinary practices to use in the run up to, and during TAC. This includes leaflets, invoice stickers, a veterinary practice toolkit featuring an owner evening presentation, editorial copy for newsletters and websites and images to support the campaign.
For further information on TAC or Prascend, the first licensed product for the treatment of Cushing's Disease, please visit http://www.talkaboutcushings.co.uk/, contact your Boehringer Ingelheim Vetmedica territory manager or call 01344 746959.
References
1. Donaldson et al. “Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis”. JAVMA, Vol 224, No. 7, April 1, 20042. McGowan. “Diagnostic and Management Protocols for Equine Cushings Syndrome” In Practice, November/December 20033. McGowan. “Epidemiology and Clinical Perspectives of Endocrinopathic Laminitis”, BEVA Congress 2009
Kruuse UK has announced that it will be launching its new Android telemetric ECG system at BEVA 2011.
The original Televet 100 supports transmission of ECG data to a range of approx 100m (330ft), allowing recording and displaying of real time data only within a confined lunging or riding arena. By linking this system to a mobile network via 3G Android phone and a Windows 7 based tablet PC, the new Televet system overcomes this range limitation.
The new system requires the rider/horse to carry a 3G mobile phone which transmits data over the mobile internet, allowing the veterinary surgeon to display and record real time data on any PC/laptop with internet access or mobile internet connection. This also includes GPS information collected by the phone allowing the ECG, heart rate and velocity of the horse to be displayed in parallel.
The Android Telemetric ECG system is specifically targeted towards veterinary applications in the field of sports horses where extended range is particularly useful, such as endurance riding, three day eventing and racing.
Televet software can now also be integrated in Dicom infrastructures in practice for data capture and recording.
Sarah Stokes, Kruuse Equine Territory Manager said: "the flexibility and simplicity of the system along with immediate access to ECG data of patients will be an invaluable diagnostic tool for UK vets allowing vital support for patients and owners wherever they are."
Visitors to the Kruuse stand at BEVA 2011 will also have the chance to win an Acer ICONI W500 tablet worth £500.
A research project funded by The Horse Trust has made important discoveries about how two peptides regulate the inflammatory response in horses. This knowledge could help with the development of improved anti-inflammatory drugs, which are used to treat a wide range of conditions in horses.
The research project was led by Professor Fiona Cunningham at the Royal Veterinary College in Hertfordshire and Dr Karen Rickards at the Donkey Sanctuary in Sidmouth, assisted by Dr Andrew Brooks at the RVC, and by Dr Kirstie Pickles, now at the Royal (Dick) School of Veterinary Studies in Edinburgh.
Inflammation is associated with a wide range of equine diseases, including recurrent airway obstruction, laminitis and sweet itch. Anti-inflammatory drugs, such as glucocorticosteroids, mainly work by blocking the formation and/or actions of compounds produced in the horse's body that cause inflammatory responses. However, these drugs are not always effective and can have unwanted side effects.
This research, funded by The Horse Trust, aimed to find out more about two naturally-occurring peptides - chains of amino acids that are shorter than proteins - known as annexin-1 and CXCL8. Both have been shown to affect the inflammatory response but little research has been done on their effects in horses. In the long term, knowing more about these compounds could help in the development of new anti-inflammatory drugs with fewer side effects.
During inflammation, neutrophils (a type of white blood cell) stick to the cells lining blood vessels and migrate into inflamed tissue, where they ingest and break down harmful agents. Using techniques that mimic these events, CXCL8 was found to cause adherence and migration of horse neutrophils. However, when it was used in combination with another pro-inflammatory substance, neutrophil migration and adherence were markedly decreased. This suggests that attempts to reduce inflammation by blocking the actions of CXCL8 might not be as beneficial as had been thought.
At the start of the project, the researchers had no information about horse annexin-1, other than its gene sequence, so their first step was to develop a method to detect the peptide in white blood cells. They established that it was present and, as horse annexin-1 has not yet been synthesised, they used a synthetic peptide derived from annexin-1, Ac2-26, to look at the effects on horse neutrophils.
They found that Ac2-26 decreased neutrophil adherence and migration in response to other pro-inflammatory compounds, although at high concentrations the peptide itself caused some cell activation, thereby increasing inflammation. They also found that dexamethasone (a glucocorticosteroid) increased the levels of annexin-1 in cells, indicating that, as in humans, this class of drugs is likely to act in part through the formation of annexin-1.
These findings suggest that the use of compounds which mimic the actions of annexin-1 may have limitations as anti-inflammatory drugs. As glucocorticosteroids partly work by forming annexin-1, further research is needed in order to find out how annexin-1 will act in the horse's body and establish how its formation contributes to the beneficial effects of these drugs.
Professor Cunningham said: "This Horse Trust-funded research has resulted in some very interesting findings about how inflammatory cells are regulated in horses. The receptors that annexin-1 and CXCL8 act upon could be targets for new equine inflammatory drugs, but more research is needed first to fully understand their actions and how they produce these effects."
The team's research has been accepted for publication by the journal Veterinary Immunology & Immunopathology.
Kruuse is to launch a new Manuka honey dressing at BEVA 2011 in September.
Kruuse says that honey has been used as a topical anti-microbial agent and dressing for over 2000 years, and that honey derived from the nectar of the Manuka tree (Leptospermum scoparium) has its own unique chemical properties. Manuka honey contains glucose oxidase imparted by the bees during its collection and storage. This enzyme facilitates low level release of hydrogen peroxide when in the presence of wound exudates and thus supports cellular proliferation and metabolism through an antioxidant effect. The high sugar and low pH content creates a high osmotic potential which gives honey excellent debridement and anti-inflammatory properties.
The company says that one of the biggest difficulties with the use of honey in wound dressings is ensuring that once applied it stays over the wound area. Many attempts to coat dressings have been unsuccessful; often the active honey ingredient is left within the packaging severely reducing the effectiveness of the dressing. Kruuse says its Manuka dressings have the active honey impregnated 'within' the dressing, which ensures precise and easy application even if wearing surgical gloves.
The Kruuse Manuka dressings range comes in impregnated adherent (Kruuse Manuka AD), non-adherent dressing (Kruuse Manuka ND) and 15g tube of Manuka G. Each dressing comes in 3 sizes 5x5 cm , 10x12.5 cm and the KRUUSE Manuka roll (10x100 cm) a unique product ideal for large vertical wounds. E.G. Equine forelimb.
Kruuse also says that the antimicrobial potency in Manuka honey is rated by a standardised rating known as Unique Manuka Factor (UMF). The higher the UMF the better the antimicrobial effect. A minimum UMF of 10 is required to ensure sufficient effect in the wound environment, Kruuse Manuka Honey Wound Dressings have a Unique Manuka Factor of 15.
There is a restricted annual supply of Manuka honey as this unique product supply is controlled by a small number of producers in New Zealand. Many current honey products available use blends of Manuka honey with other poorer quality honey, these are often less effective. Kruuse Manuka uses 100% Manuka honey in all its dressings with the profits of the sale being returned directly to the Maori tribe that oversee the production of Manuka honey.
Andrew Groom, Managing Director Kruuse UK Ltd. said: "I am very excited that we have been able to secure a direct connection to supply this unique product with the knowledge that the Maori suppliers will see the returns for generations to come whilst this new range of dressing will add huge versatility for day to day wound management!"
Merial Animal Health has announced that the duration of immunity for the tetanus component of Proteqflu-Te has been extended to 2 years.
Merial's Veterinary Technical Manager Kevin Whelan said: "This is a welcome new addition to the label claims for this advanced vaccine, which is the only equine flu vaccine in the UK to contain a recently updated influenza virus strain. The updated strain, innovative canarypox vector technology and now the extended tetanus duration of immunity claim make the vaccine an excellent choice for vets in the UK"
Merial says Proteqflu-Te can now be used on an alternate year basis in combination with the company's other flu vaccine, Proteqflu, which does not contain tetanus toxoid. The one year duration of immunity for the influenza component remains unchanged.
Please contact your local Merial Representative or the Merial Technical Support line on 0870 6000 123 for further information.
Pfizer Animal Health has launched PrintRoom, an online printing service to help equine practices deliver high quality communications to their clients, to support the company's Equip range of equine vaccines.
PrintRoom can be used to produce customised vaccination reminder cards, invitations, letterheads, stable name sheets, and more.
You can choose from a palette of designs, images and colours and can also upload your own logos and images to tailor your client communications to your preferred style.
PrintRoom has a MailMerge option to pre-address all your mailings and you can pay for postage and set the date of despatch online, to help ensure boosters are administered on time and passports stay up to date.
Paul Blanc, Equine Brand manager at Pfizer said: "Good communication with your clients plays a vital role in maintaining vaccination compliance and retaining and gaining business. Our print room service makes it easy to produce a broad range of customised practice marketing materials to a very professional standard that stand out from the crowd."
For further information visit http://www.pfizerprintroom.com/, call 0845 6027439 or contact your Pfizer Account Manager.
The Animal Health Trust has cut the first sod of a new cancer centre for animals in Suffolk.
The AHT's Cancer Centre will provide all three treatment options: surgery, chemotherapy and radiotherapy, on one site. The cancer facility is being purpose-built to treat horses, dogs and cats.
Sue Murphy, Head of Clinical Cancer Treatment at the AHT, said: "Having all three treatment options on one site means that whatever the diagnosis, we will be able to offer each and every patient the very best options for their specific case. With one in four dogs and one in six cats developing cancer at some time in their life this new centre will help many more animals - from Suffolk, East Anglia and all across the UK."
The new centre will also further research into cancer. Treating animals with all types of the disease will enable the AHT's vets and scientists to expand current knowledge about cancer. This will help with the development of new ways to diagnose and treat the disease.
Vets and scientists at the AHT already work collaboratively with cancer researchers looking at the disease in humans. There are a number of links between human and animal cancers which have already been identified. It is hoped that knowledge gained from the AHT Cancer Centre may also help in the understanding of cancer in people.
The AHT hopes the building will open in summer 2012 . It is launching an appeal to raise much needed funds to equip the centre with a linear accelerator. This piece of specialist equipment works by delivering high-energy radiation beams to break cancerous tumours down while sparing the surrounding normal tissue.
The AHT Cancer Centre will be one of only six veterinary facilities in the UK to house a linear accelerator.
Sue Murphy added: "Currently, there is no way to tell which animals will, and which animals won't, develop cancer. It could happen to any animal at any time. This new centre will give more animals a fighting chance of beating the disease, enabling them to lead long and healthy lives. The fact that treatments developed to benefit our pets may also lead to improvements in the prevention and treatment of cancer in humans makes this centre all the more important.
"I would urge you to donate whatever you can to help equip the centre. Your donation, however large or small, will help many more animals beat cancer and it may also help in the fight against cancer in people."
If you would like to make a donation to the AHT Cancer Centre please visit www.aht.org.uk or telephone 01638 555648.
Alternatively you can make a £5 donation by textingVETS24 £5 to 70070
Pfizer has repeated it's call for veterinary practice staff to take part in its Vet Support+ independent, industry-wide survey of employee engagement.
The survey gives practice team members, who are not partners or owners, the chance to have their say about their role and career and the future of the profession. Participants are asked to consider how they feel towards their practice and delve into issues on teamwork and communication, management techniques, personal development opportunities and working environment.
More than 3,000 vet practice staff have already completed the survey, a phenomenal early response which suggests practice employees are keen to have their voices heard. However, the closing date for the survey isn't till Friday 29th July, so if you haven't yet had a chance to do the survey, there is still time.
Pfizer Business Consultant, Vanessa Wilson, has more than 20 years experience helping businesses, teams and individuals achieve their goals. She is not surprised at the significant early response: "Questions on the level of employee engagement and satisfaction come up all the time in the work we do with practices. I'm not surprised that staff are using this opportunity to have their voice heard.
"Once completed, this survey will provide some very useful data and direction for the industry as a whole and I'd like to think it will identify opportunities for both individual career development and practice growth."
All members of staff employed within a practice who have not received a mailing and wish to participate are welcome to respond online. http://www.noesis-mi.com/surveys/employeesurvey/.
Pfizer says the findings, which are expected to be released in the autumn, will deliver a national and regional view of the current employee engagement landscape.
For further information about Vet Support+ Business Services from Pfizer visit www.vetsupportplus.co.uk.
The Land Rover Burghley Horse Trials has announced a £15,000 bursary to the Animal Health Trust. The bursary will be used to help fund the development of a rapid result blood test to identify horses infected with Strangles.
The AHT has already developed a test that can detect the disease, however the result is not known for 48 hours. The aim of the new research is to develop the test to produce a result within 10 minutes. The test, which is being developed in conjunction with Forsite Diagnostics Ltd, will be a useful tool for disease screening at sales and competitions.
"As an independent charity we receive no government funding and this bursary is extremely important to us and we are delighted to be working in partnership with The Land Rover Burghley Horse Trials on this specific project," said Dr Richard Newton of the AHT who is carrying out the research in partnership with Professor Andrew Waller. "Without this vital funding to carry out the painstaking work that will give us the confidence to launch the test, it will remain no more than a theoretical possibility."
The Bursary will be presented at this year's Land Rover Burghley Horse Trials (1- 4 September 2011) - in recognition of the 50th Anniversary of the event.
"With increasing horse movement, not only world-wide but closer to home between competitions and livery yards, preventing the spread of disease is an increasingly important challenge facing the horse world," said Elizabeth Inman Director of the Trials. "We are delighted to be able to play a part in this challenge and hope that this anniversary bursary will help to fast-track this new test out of the laboratory and into the field and thereby help reduce the spread of what is a horrible disease for horses and owners."
BCF Technology has launched a competition in which the person who submits the best photograph with the theme of: All in a day's work - animal imaging, will win an iPad 2.
To enter the competition, you need to post your photographs, (and tell BCF a little about the story behind the images) at www.facebook.com/bcftechnology or email them to: info@bcftechnology.com
Jason Rogers, Marketing Manager at BCF said: "We wanted to create a fun way to show just how interesting and different each days work is when imaging animals. We have made the competition open to all that work with animal imaging including our staff, dealers and vets, vet nurses, animal contractors, etc from all over the world.
"It is great to see the BCF office in the States and our international dealers also promoting the competition in their own countries, making the competition truly international. Response to the competition has been fantastic - see our facebook page to some entries for yourself."
The closing date for the competition is 30th September 2011.
For more information, visit: www.bcftechnology.com
Vetoquinol UK Ltd is launching a dedicated large animal/equine sales force on the 1st July.
The company says the move reflects the change in cattle and equine veterinary practice to become specialists.
Vetoquinol's large animal brands include: Marbocyl®, Sedalin®, Equistro®, Tolfine®, Pro Rumen and Locatim®.
The new team comprises:
The new sales team will be managed jointly by Hugh Gibson and Stuart Wade.
For further information or to make an appointment please contact your local Territory Manager direct or telephone 01280 825424
The National Office of Animal Health has completed its annual review of its Code of Practice for the Promotion of Animal Medicines, and a number of changes will come into effect on 1st July 2011.
One change spells out the way antimicrobial medicines are promoted to farmers, with a firm emphasis on correct use and education.
Advertisers will be required to describe the condition the product is aiming to treat, and to promote an understanding of the treatment of the disease.
The phrase "use medicines responsibly" will always be included in text, making the voluntary strapline introduced in 2009 a formal part of the NOAH Code. As with all promotions to people other than prescribers, farmers will always be reminded to consult their veterinary surgeon.
Advertising text will always state clearly the name of the company and the brand being promoted, and promotion must not be designed to disguise its real nature.
Withdrawal periods for products will be stated, but these must not be unduly prominent and not in a font size greater than the body copy containing recommended dosage and species description.
The changes were proposed by NOAH within its formal response to the Veterinary Medicines Directorate's consultation on the Veterinary Medicines Regulation 2010. The Minister decided in December 2010 to continue to allow the advertising of antimicrobial veterinary products to farmers.
Phil Sketchley, NOAH Chief Executive, said: "Whilst welcoming the Government's decision in December not to further restrict the advertising of animal medicines, we feel that the industry should take a proactive role to ensure the system works properly. We believe it is important for farmers, who are legally responsible for the health and welfare of their animals and the food produced from them, to be aware of the medicines that are available to protect the health of their animals, and at the same time we want them to know that these medicines must be prescribed and used responsibly.
"The issue of antimicrobial resistance is one that affects us all. The way to promote best practice is through education by maintaining all lines of communication between farmers, vets, scientists and animal medicine producers.
"Antibiotics are essential for maintaining the health and welfare of all animals, but like any medicine they need to be used responsibly in order to maintain their effectiveness, and their availability for future generations."
BCF has announced the launch of the Medison Sonovet R3 portable ultrasound scanner.
BCF says the R3 is the next evolution of the Pico from Medison which is ideal for both equine and small animal vets. It is now more compact with a robust design with enhanced image quality and improved frame rate, and even at a lower price.
Graham Howe, Partner at Stow Veterinary Surgeons in Gloucestershire has one of the new machines. He said: "We chose the Medison R3 for several reasons. The R3 is an excellent quality machine at the right price and provides excellent value for money. We wanted Doppler and the R3 provides this without breaking the bank.
"The scanner has increased our diagnostic capabilities and enabled us to diagnose increasingly subtle lesions in small animal anatomy.
"We also knew from previous experience with previous with an ultrasound scanner and digital X-ray machine that we could rely on BCF for support."
For more information visit http://www.bcftechnology.com/, or call +44 (0)1506 460023 to arrange a demonstration.
BEVA is giving its members the opportunity to participate in a free practice benchmarking survey, to help them ensure their business is being run as efficiently and profitably as possible. The results of the research will be released at BEVA Congress, 7th-10th September 2011.
The Association has worked with Hazlewoods, chartered accountants and business advisors to the veterinary profession, to develop a detailed benchmarking questionnaire for equine veterinary practices, which allows businesses to compare their practice, anonymously, with other similar practices. The report should identify areas for profit improvement, including practice structure and pricing and may also highlight other potential methods of income generation.
Mark Beaney, partner at Hazlewoods and specialist advisor to the veterinary profession, said: "This is a super opportunity for equine practices to obtain helpful, free advice on how to fine-tune their business for maximum efficiency, delivery and profit. The questionnaire should take no more than half an hour to complete and in return we will provide you with a confidential individual report, with your practice data benchmarked."
Mark will present an overall report on the equine veterinary market at BEVA Congress on Saturday 10th September. All participating practices will remain anonymous. The benchmarking survey can be downloaded from the BEVA website at: http://www.beva.org.uk/news/view/59 and must be completed by 30th June 2011.
BEVA Congress runs from 7th-10th September 2011 at the Liverpool Arena Convention Centre, Liverpool. This year BEVA will be celebrating its 50th anniversary - for further information and to register visit http://www.beva.org.uk/.
The Fédération Équestre Internationale (FEI) has added Metacam for Horses to its 'list of detection times'.
According to the manufacturer, Boehringher Ingelheim Vetmedica, Metacam (meloxicam) is the first preferential COX-2 inhibitor to be added to this list, and has stated plasma and urine detection times of 72 hours administered intravenously or orally1. This is the shortest urine detection time of the NSAIDs available for use in horses, and compares to the 168-hour (7 days) detection time for phenylbutazone stated by the FEI.
Craig Beck, equine sales and marketing manager for Boehringer Ingelheim in the UK and Ireland said: "We have been very happy to work in partnership with the FEI to provide the robust data that has supported the FEI in their analysis of Metacam. Metacam is an important addition to the FEI list, that will help vets treating competition horses. There is now a modern and proven NSAID which extends the therapeutic options available to vets."
Metacam is licensed in horses for the alleviation of inflammation and relief of pain associated with musculo-skeletal disorders or colic.
For further information, please contact your Boehringer Ingelheim Vetmedica territory manager or call 01344 746959.
1 Detection Time agreed with the European Horse Racing Scientific Liaison Committee (EHSLC)
Eurovet has launched Relaquine 35 mg/ml Oral Gel for Horses - a licensed acepromazine (ACP) in a gel format.
The company says Relaquine can be used to sedate horses for examination and in stressful situations that some horses find hard to deal with such as farriery, box rest, dentistry and clipping where highly-strung horses can cause problems. Relaquine is administered orally or mixed with food and is available as an adjustable syringe format containing 10 ml of gel.
Relaquine is the fourth product launch this year by Eurovet and the company says there is more in the pipeline for 2011.
Relaquine Oral Gel is expected to be available to order from veterinary wholesalers from Monday 16th May. Eurovet is also offering an introductory promotion: for further details contact Eurovet on 01223 257933.
VetSurgeon member Viki Edmondson MRCVS is taking part in a drive to help 13-year-old Octavia Woodward, who was born with spinal muscular atrophy (SMA), raise £100,000 to help The SMA Trust.
Viki, a well-known vet in the carriage driving world, will be joining Octavia on 'Octavia's Mad Marathon', a five-day, 110 mile carriage drive from Windsor to Wincanton.
Octavia will be driving her pony, Diddy, with her mother Henrietta as co-driver. Meanwhile, Viki will be driving a pair of Gelderlander horses. They'll be leaving the main ring at the Royal Windsor Horse Show with a support crew at 3:30pm on 13th May.
Viki graduated from Bristol Veterinary School in 1993. Since 2001 she has run her own equine practice plus a small animal surgery from the Newdigate, Surrey farm she shares with husband Peter. Viki has known Octavia since she was born and it was Viki who paired up Diddy with Octavia and encouraged her to progress from walking round the roads to the excitement of "off-roading". Viki will be providing support and encouragement to Octavia during the trip - of course with any veterinary help being close by.
To support Viki and Octavia, visit: http://www.justgiving.com/vikithevet
Defra has announced plans to form a new Animal Health and Welfare Board for England which will bring experts including farmers, veterinary surgeons, welfare experts and others from outside Government together with the Chief Veterinary Officer and civil servants to make direct policy recommendations on policy affecting the health and welfare of all kept animals such as farm animals, horses and pets.
According to Agriculture Minister Jim Paice, it is the first time that people affected by Government policy on animal health and welfare will make recommendations on those policies directly to Ministers.
Mr Paice said: "This is a completely new way of working. It replaces the old ways, where the people most affected by decisions were kept at arm's length from policy making on those subjects.
"This is about the Big Society not just existing in our communities, but in the heart of Government - helping to put the decisions in the hands of those who are doing the work on the ground.
"We've already seen the success of a partnership between farmers and the Government with the work that's been done on bluetongue - which has seen the disease virtually eradicated in this country."
Final decisions on animal health and welfare policy will remain in the hands of Government Ministers.
The Board will be made up of around 12 members, 5 senior Defra officials including the Chief Veterinary Officer, and 7-8 external members including the chair. The external members will have experience and knowledge of kept and farmed animals, animal and veterinary science, and animal welfare, and could be farmers, veterinarians, animal welfare experts.
The Board and its members will have to represent the views of all stakeholders so will be expected to communicate with them regularly.
The Board's responsibilities will include:
The Board will not be set up as a non departmental public body or arms length body. It will form part of the internal structure of Defra.
Commenting on the announcement, Harvey Locke, President of the British Veterinary Association, said: "The BVA is delighted that both the Advisory Group and Ministers have taken note of the veterinary profession's views in drawing up these plans.
"We said from the outset that genuine responsibility sharing has to be achieved before cost sharing can be discussed and we warned against earlier plans to separate animal health policy from animal welfare policy, as the two are intrinsically linked.
"Animal health and welfare policy issues require expert, scientific input and it will be essential that the new Board includes veterinary representation. We believe that the Board will provide the right mechanism for ensuring decisions are based on sound science.
"The new Board will also have to work closely with the three devolved administrations to ensure that animal health and welfare policies across the UK are joined up and complementary."
Alstoe Animal Health has announced that Vetergesic (buprenorphine), the UK's most commonly used injectable opiate for small animal use, is now registered for use in horses.
Developed and manufactured in the UK, Alstoe took over marketing Vetergesic 11 years ago. Two years ago the company introduced the Multi-Dose Pack, which it says allows veterinary surgeons to manage the larger liquid volumes required in horses more easily.
Alstoe says Vetergesic potentiates sedative drugs for standing sedation or routine premedication and provides profound centrally acting analgesic effects for up to nine hours. In routine procedures, this allows good recoveries and a rapid return to normal behaviour patterns.
Alstoe also says that in a thermal anti-nociceptive study carried out at Bristol University, Vetergesic showed significantly better analgesic effects than butorphanol. Field studies carried out in the UK also confirmed that when combined with a sedative, Vetergesic can provide up to 60 minutes of operating time, with smooth and quick recoveries.
John Nellis of Alstoe said: "We have invested heavily in this product and are confident that the rewards enjoyed by small animal vets will also be appreciated by their equine colleagues. We call Vetergesic 'the thoroughbred of pain management'."
Vetergesic Multidose is available for dogs, cats and horses in a 10 ml vial.
Alstoe offers an hour long explanatory seminar, which can be delivered directly to practice members. An 8 page brochure and 'pocket-sized' dose chart are also available. Further details from Alstoe on: 01347 878606 or email: info@alstoe.co.uk .
Ceva Animal Health has introduced an improved version of Hepatosyl, its liver support supplement for horses.
Hepatosyl Plus for horses contains the same antioxidant ingredients as the original version but now also contains Silybin, the most active isomer of Silybum marianum (milk thistle)1.
According to Ceva, the addition of Silybin gives new Hepatosyl Plus a triple antioxidant approach to liver support to help neutralise free radicals within the liver. Free radicals are produced by hepatocyte mitochondria and cause oxidative damage to cell membranes, protein and DNA.
The company says Hepatosyl Plus's triple approach includes S-adenosylmethionine (SAMe), in a stable, pure and absorbable form, which is converted into the potent liver anti-oxidant glutathione and also helps to maintain bile flow; Vitamin E, which is well-known as a potent liver antioxidant, and Silybin, which works as an antioxidant by increasing cellular superoxide dismutase.
Hepatosyl Plus remains the only liver supplement to contain Vitamin K which is needed by the liver for the production of many essential clotting factors, such as factors II, VII, IX and X, making it ideally suited for pre and post anaesthetic liver support.
Ceva says an independent trial2 on horses with confirmed liver disease has demonstrated the benefits of Hepatosyl. Conducted by European Specialist in equine internal medicine Dr Tim Brazil, the trial involved seven horses of various ages and types. All animals were given Hepatosyl in addition to treatment with antimicrobials, corticosteroids, a low protein diet and vitamin B supplementation. Post SAMe supplementation tests revealed a notable reduction in raised liver enzymes, serum proteins and bile acids and the seven horses showed obvious improvements including better appetite, weight gain and demeanour.
For further product information contact Ceva Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
References1 Flatland B (2003) Botanicals, Vitamins and Minerals and the Liver2 Brazil T (2007) S-adenosylmethionine liver support supplement trial in horses
The results of the UK's first ever public National Equine Health Survey have quantified non-notifiable healthcare issues affecting horses, ponies, donkeys and mules in the UK.
The survey, which was pioneered by The Blue Cross animal charity and is supported by The British Equine Veterinary Association, was carried out last November following two years of pilot schemes. The intention was to find out more about endemic non-notifiable diseases that have never before been recorded in horses, ponies, donkeys and mules, such as coughs, skin diseases and lameness.
The results were announced at the National Equine Forum by Professor Josh Slater, Professor of Equine Clinical Studies at The Royal Veterinary College, who has been working with The Blue Cross on the survey.
A total of 306 sets of records were submitted from 3120 horses in mainly private ownership, with a balance of representation from competition yards, riding schools, welfare charities and studs. A broad range of syndromes and diseases were assessed including colic, sarcoids, laminitis, wounds, dental issues, eye disease, lameness and weight issues.
The results showed that lameness was the most common problem affecting horses (11% of horses surveyed) but that the foot was not the most common cause of lameness and that laminitis (3%) was less common than the 7-8% total that previous surveys had suggested.
Weight management was the next most common issue for horse owners, with 9% of horses recorded as overweight and 8% as underweight. These figures are lower than previous surveys which may be because they are based on the owner's assessment of their horse's weight which is subjective and may vary according to their perception of 'the right weight'.
Skin disease and wounds (5% and 4% respectively) posed a significant problem and colic (2%) was also a common occurrence, with a 6:1 ratio between medical and surgical cases.
The survey is breaking new ground in Europe as well as the UK. Currently Government agencies in all European countries conduct surveillance for prescribed exotic diseases such as West Nile Virus and African Horse Sickness but currently there are no large scale surveillance programmes for endemic diseases.
Professor Slater said: "The regular collection of such data holds numerous benefits to the UK equine industry. Not only does the survey provide a benchmarking facility for equine disease, welfare, standards of care and codes of practice but it will also underpin standards for yard inspection schemes. Not least it confirms the workability of an important template to monitor the serious threat of infectious and exotic disease in the future."
He added: "It's exciting to see hints in the NEHS 2010 survey that data 'straight from the horse's mouth' might challenge some established ideas. For example; the survey found that lameness was common, as you would expect, but that the foot was not the most common cause of lameness, which you might not have expected. This kind of data has never been collected before and is invaluable to the veterinary profession and wider animal welfare industry, helping to inform our future research, training and education. It will be really exciting to see the results of the larger surveys The Blue Cross are running in 2011."
Kerry Doyle, education officer at The Blue Cross said: "We are thrilled to be involved with this innovative project to enhance the future health of our horses and very grateful to all those who have participated in the survey so far. We now need even more horse owners to sign up for the next round so that we can capture as much useful data as possible."
The National Equine Health Survey is currently funded by The Blue Cross but sponsorship is being sought. It is to be conducted twice-yearly with the next census week planned for 9-15 May 2011. All keepers and owners of horses are urged to participate and details of all horse owners will remain anonymous. It's very quick and easy to complete and should only take around five minutes. To register online visit www.bluecross.org.uk/NEHS or email NEHS@bluecross.org.uk.
Ceva Animal Health has renamed Tildren, its tiludronate-based bisphosphonate infusion for the treatment of bone spavin in horses, as Equidronate.
Tiludronate has been used to treat bone spavin and navicular disease in Europe for many years and was licensed for bone spavin in the UK in 2008. Ceva says trials published last year show that horses suffering lameness caused by bone spavin can show marked improvement following treatment with an Equidronate infusion, in combination with controlled exercise.
Bone spavin is a chronic aseptic osteoarthritis of the distal tarsal joints and is considered to be one of the most common forms of hindlimb lameness in the horse. Horses with bone spavin experience abnormal bone remodeling changes. According to the company, Equidronate helps to modulate the osteoclasts to help prevent excessive bone removal and give the osteoblasts a chance to catch up. This in combination with adjusting levels of exercise helps to harmonise the bone adaptation needed for the horse to perform its athletic duties.
In the trials one in four horses showed marked improvement; two in four showed improvement, which, when combined with other treatment, enabled the horse to resume former levels of activity and one in four horses showed no response.
Ceva Animal Health has produced a range of explanatory leaflets for horse owners on bone spavin, navicular disease and sacroiliac disease, as well as a helpful booklet detailing the discharge procedures for horses that have been treated with Equidronate.
For free copies and for further product information contact your Ceva sales representative, ring Ceva on 01494 781510 or visit the website at http://www.ceva.uk.com/